ISCT 2009 Corporate Tutorials and Symposia
Here is a listing of the corporate tutorial and symposia sessions being held at the International Society for Cellular Therapy conference Sunday-Wednesday in San Diego. For more information see www.celltherapy.org.
| ISCT 2009 Corporate Tutorial and Symposium Listing | ||
 |
 |
|
Sunday May 3, 2009 Miltenyi Biotec |
|||
|
Emerging treatments enabled by cellular therapy Topics and Speakers: Notch-mediated expansion of human cord blood stem/progenitor cells: cell processing and translation to the bedside NK cell therapy in the pediatric leukemia Antiviral T cell immunotherapy—present and future perspectives The role of cell processing in the emerging regenerative medicine applications |
Time: 3:00pm – 5:00pm / Grand Ballroom B|
Monday May 4, 2009 WuXi AppTec |
|
Topics and Speakers: Validation of a rapid PCR method for the detection of mycoplasma contaminants according to European Pharmacopoiea 5.8, 2.6.7, 2007. Use in release testing of cell therapy products. Recent publication of a revised section for mycoplasma testing in the European Pharmacopoeia (5.8, section 2.6.7) has led to interest in validating a nucleic acid amplification technique for use in detection of mycoplasma contaminants in cellular therapies. The replacement or supplementation of the existing culture based methods with a PCR-based method has several advantages for the biopharmaceutical industry, mainly with respect to turnaround time for results, and cost. Replacement or substitution of existing methods by a PCR method requires the demonstration of equivalent assay LOD and specificity. The experimental requirements for this comparability validation have been spelled out in detail in the EP section referenced above. In this presentation, we describe the validation and comparability analysis of a PCR method exactly according to the EP guidance. Completion of this validation activity has resulted in the availability of an assay that meets or exceeds EP compliance requirements for a mycoplasma detection method. Comprehensive testing panels for cellular therapeutics. In this presentation WuXi AppTec will describe the current regulatory landscape for appropriate testing programs for cellular therapies, focusing on safety and identity assays. A multiuse contract manufacturing facility for the production and release of cellular therapies. WuXi AppTec will present a summary of the design and operation of the contract GMP cell therapy and cell banking facility located within the Philadelphia site. Design, start up and validation activities will be discussed with reference to specific projects and case studies. |
Time: 7:30am – 8:30am / Nautilus 4|
Monday May 4, 2009 CellGenix Technologie Transfer GmbH and |
|
Topics and Speakers Application of DC Maturation and T Cell Expansion in a Clinical Setting Purpose: Description of methods and materials for DC maturation and autologous T cell expansion in cancer therapy and a report of clinical outcomes. Expansion of Young Tumor Infiltrating Lymphocytes (Y-TIL) as a Therapeutic Agent in Cancer Treatment Purpose: Description of materials and methods used for a therapeutic Y-TIL expansion protocol Description of Materials and Methods for Cord Blood Expansion with Clinical Outcomes Purpose: The application of double cord transplants with one expanded cord using cytokines and notch ligand, and one cord left unmanipulated in cancer therapy. |
Time: 12:15pm – 1:30pm/ Nautilus 2|
|
|
Come join the leading innovators in cell therapy for a breakfast session on safer cell therapies. Chair Eric Roos, Business Development Leader, Stem Cell Therapy, Life Technologies Corporation Panelists Leslie Wolfe, PhD, VP, Technology Development, Cellular Therapies, Genzyme Biosurgery Patricia Whelton, Senior Director, Regulatory and Process Development, Osiris Therapeutics, Inc. John T. Kemshead, PhD, Director, Clinical Affairs, Baxter Cellular Therapies
For more information on the session: www.invitrogen.com/isctmeeting |
|
Tuesday May 5, 2009 |
|
Culture and expansion of cord blood MNCs enriched by the Pall Purecell Select System, a new alternative to density gradient Description Speaker |
Time: 12:30pm – 1:30pm / Nautilus 1|
Tuesday May 5, 2009 |
|
From Stem Cell Banking to Bedside Biosafe is honoured to have 2 renowned experts presenting some of the leading advances in the field of cellular therapy. Topics and Speakers Dr. Joanne Kurtzberg, Chief of Pediatrics and Blood & Marrow Transplantation at Duke University, NC, USA will provide an overview of the Carolinas Cord Blood Bank, one of the world’s largest and most respected public cord blood banks, before presenting recent developments in the use of cord blood to treat non-haematopoietic diseases. Dr. Riccardo Saccardi from the Haematology Department, Careggi University Hospital, Florence, Italy, will present the different work performed by his laboratory in the study and therapeutic use of cellular products. Careggi is Europe’s leading transplant centre for autoimmune diseases and Dr. Saccardi will go on to discuss the use of stem cells in the treatment of such diseases. |
Time: 12:30pm – 1:30pm / Nautilus 2 
Tuesday May 5, 2009
Time: 12:30pm – 1:30pm / Nautilus 3
BioLife Solutions Inc.
|
Biopreservation Yield in Cell Therapy: Process Optimization Description Bio |
|
Wednesday May 6, 2009 |
|
Topics and Speakers Expansion of Mesenchymal Progenitor Cells (MPCs) in a Novel Serum- and Animal Component-Free Culture Medium To address the need for serum-free MPC culture, STEMCELL Technologies has developed a novel serum- and animal component-free culture medium which promotes superior clonogenic growth and long-term expansion whilst maintaining multi-lineage differentiation potential of human bone marrow-derived MPCs. Dr. Ravenska Wagey will present performance characteristics of the medium as well as optimal procedures for the isolation, characterization and expansion of MPCs. A Rapid Hematopoietic Colony Assay for Measuring the Potency of Umbilical Cord Blood Grafts To meet the need for rapid and easy-to-use potency assays, STEMCELL Technologies has developed a new hematopoietic colony assay that can be completed in 7 days, is easier to score than standard CFU-assays and provides accurate measurement of hematopoietic progenitor cell frequencies in cord blood units that correlate well with results of standard CFU-assay formats. Dr. Michelle Bowie will present an overview of the hematopoietic CFU assay as well as the performance characteristics of STEMCELL’s 7-day CFU-assay. |
Time: 12:00pm – 1:00pm / Grand Ballroom B
